

# Asian Journal of Research in Chemistry and Pharmaceutical Sciences

Journal home page: [www.ajrcps.com](http://www.ajrcps.com)



## A NEW RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF TENELIGLIPTIN IN BULK AND TABLET DOSAGE FORM

Shubham Bonde<sup>\*1</sup>, Vikram Thakare<sup>1</sup>, Shilpa Chaudhari<sup>1</sup>

<sup>1\*</sup>Department of Pharmacy, Dr. D Y Patil College of Pharmacy, Akurdi, University of Pune, Maharashtra, India.

### ABSTRACT

Teneligliptin is a type 2 diabetic drug used for Diabetes [HYPERLINK "https://en.wikipedia.org/wiki/Type\\_2\\_diabetes\\_mellitus"](https://en.wikipedia.org/wiki/Type_2_diabetes_mellitus) mellitus. And it is also belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or commonly known as "gliptins". A simple, sensitive and accurate RP-HPLC method has been developed for the determination of Teneligliptin in bulk formulation. The  $\lambda_{max}$  of the drug was found to be 246nm in mobile phase containing Methanol: Phosphate buffer pH 3[70:30(v/v)]. The method shows high sensitivity with linearity 10 to 50 $\mu$ g/ml (regression equation:  $y = 54647x - 74133$ ;  $r^2 = 0.9968$ ). The various parameters according to ICH guidelines are followed for validating and testing of this method. The Detection limit and quantitation limit were found to be 0.109 $\mu$ g ml<sup>-1</sup> and 0.3305 $\mu$ g ml<sup>-1</sup> in Methanol: Phosphate buffer pH 3[70:30 (v/v)] respectively. The % purity of tablet formulation was found to be 99.57%. The results demonstrated that the procedure is accurate, specific and reproducible (RSD < 2%), and also being simple, cheap and less time consuming and appropriate for the determination of Teneligliptin in bulk and pharmaceutical formulation.

### KEYWORDS

Teneligliptin, Dipeptidyl peptidase-4 inhibitors, RP-HPLC and Method development.

### Author for Correspondence:

Shubham Bonde,  
Department of Pharmacy,  
DR. D Y Patil College of Pharmacy, Akurdi,  
University of Pune, Maharashtra, India.

**Email:** shubham.bonde156@gmail.com

### INTRODUCTON

A new class of antidiabetic drugs, Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently introduced, that show enthusiastic results in the treatment of glycemic control with a minimal risk of hypoglycemia and weight gain<sup>1</sup>. Teneligliptin, a novel Dipeptidyl peptidase-4 inhibitor, has a unique structure which contains 5 membered rings, which produce a potent and long-lasting effect. Teneligliptin is now used as treatment in cases of insufficient improvement in glycemic control even

after diet control and exercise and also a combination of diet control, exercise, and sulfonylurea- or thiazolidine-class drugs. Tenzeligliptin is administered orally at a dosage of 20 mg once daily in adults, which can be increased up to 40 mg per day. Because of the excretion of the metabolites of this drug are via renal and hepatic excretion, no special dose adjustment is necessary in patients who having renal impairment<sup>2</sup>. Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) are doing original synthesis of Tenzeligliptin and was the first drug of its kind to be synthesized in Japan. The drug under the brand name TENERIA® is sold jointly by Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co, Ltd, (Tokyo, Japan)<sup>3,4,5</sup>.

Tenzeligliptin is 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-4-[(3S, 5S)-5-(1, 3-thiazolidine-3-carbonyl) pyrrolidin-3-yl] piperazine (C<sub>22</sub>H<sub>30</sub>N<sub>6</sub>OS) and its structure is shown in Figure No.1<sup>2</sup>.

Analytical method validation provides that various HPLC analytical techniques shall give repeatable reliable and results; As it is providing information about accuracy, linearity, precision, detection, and quantitation limits and hence it is crucial step in developing new dosage forms. ICH guideline says that, "the objective of validation of an analytical procedure is to demonstrate that it is suitable for its intended purpose"<sup>6,7</sup>. It is now mandatory in the process of drug development to provide the validation data for the responsible authorities. The Guidelines for analysis method validation include ICH guidelines. By the literature survey a very few methods reported for determination of Tenzeligliptin in bulk drug as well as pharmaceutical preparation<sup>7</sup>. This research is tries to develop a new sensitive and rapid HPLC method for the determination of Tenzeligliptin in Bulk preparation, and this method was also validated according to ICH guidelines.

## DRUG PROFILE

**Drug** - Tenzeligliptin

**Category** - Anti-Diabetic

**Structure** - Figure No.1

**Chemical Name** - (3-methyl-1-phenyl-1H-pyrazol-5-yl)-4-[(3S, 5S)-5-(1, 3-thiazolidine-3-carbonyl) pyrrolidin-3-yl] piperazine.

## MATERIAL AND METHODS

### Instruments

The chromatographic separation was performed on Analytical Technologies HPLC-3000 series compact liquid chromatographic system integrated with a variable wavelength programmable UV detector and a Rheodyne injector equipped with 20µl fixed loop. A reverse phase C18 [Cosmosil C18 (250mm x 4.6ID, Particle size: 5 micron)] was used. Model - UV 2012 double beam UV visible spectrophotometer and Wensler High Precision Balance Model: PGB 100 electronic balance were used for Spectrophotometric determinations and weighing purposes respectively.

### Reagents and chemicals

Pharmaceutical grade pure Tenzeligliptin sample was procured from Pure Chem PVT Ltd. Gujarat. HPLC grade Methanol and HPLC grade Water were procured from Merck specialities private limited, Mumbai.

### Chromatographic conditions

C18 [Cosmosil C18 (250mm x 4.6ID, Particle size: 5 micron)] was used for the chromatographic separation at a detection wave length of 246nm. Methanol, Phosphate buffer pH 3 in a ratio of 70:30 v/v was selected as mobile phase for elution and same mixture was used in the preparation of standard and sample solutions. The elution was monitored by injecting the 20µl and the flow rate was adjusted to 0.8ml/min.

### Preparation of Mobile phase

Preparation of Phosphate buffer pH 3: Dissolve 1.36g of Potassium dihydrogen orthophosphate and 2ml of triethylamine in 800ml of HPLC water, adjust the pH to 3 with orthophosphoric acid and add sufficient HPLC water to produce 1000ml. The mobile phase was sonicated for 15 min and filtered through a 0.45µm membrane filter paper.

### Preparation of Standard solutions

10mg Tenzeligliptin was accurately weighed and transferred into 10ml volumetric flasks, dissolved using mobile phase and the volume was made up

with the same solvent to obtain primary stock solution of concentration 1000 $\mu$ g/ml of the drug. (Working stock solution).

#### **Preparation of Sample Solution**

20 tablets of Teneligliptin were initially weighed and powdered and an amount equivalent to 10mg was accurately weighed into a 10ml volumetric flask, mixed with 10ml of mobile phase and sonicated for 5 min after making final volume up to 10ml with mobile phase. Then solution was filtered through 0.45 $\mu$ m membrane filter. The solution contains 1000 $\mu$ g/ml of Teneligliptin. From the above stock solution 0.1ml aliquot was transferred in to a 10ml volumetric flask, volume was made up to the mark with mobile phase to obtain a final concentration of 10 $\mu$ g/ml of metformin.

#### **Optimization of RP-HPLC method**

The HPLC method was optimized with an aim to develop estimation of Teneligliptin. Different mobile phases were tried for the method optimization, but acceptable retention times, theoretical plates and good resolution were observed with Methanol, Phosphate buffer pH 3 (70:30 v/v) using C18 column [Cosmosil C18 (250mm x 4.6ID, Particle size: 5 micron)] Table No.1 and a typical chromatograph of teneligliptin was shown in Figure No.3.

#### **Validation of the RP-HPLC method**

Validation of the optimized method was performed according to the ICH Q2 (R) guidelines.

#### **Linearity**

For the determination of linearity, appropriate aliquots were pipetted out from 1000 $\mu$ g/ml (working stock solution). 0.1 - 0.5ml was pipetted out in to a series of 10ml volumetric flasks and volume was made up with the solvent to obtain concentration ranging from 10-50 $\mu$ g/ml of metformin. Each solution was injected in triplicate. Calibration curves were plotted with concentration against observed peak areas followed by the determination of regression equations and calculation of the correlation coefficients. The calibration curves for Teneligliptin was shown in Figure No.2 and their corresponding linearity parameters given in Table No.2.

#### **Accuracy**

To ensure the reliability and accuracy of the recovery studies were carried out by % recovery method (standard addition method). A known quantity of pure drug was added to pre-analysed sample and contents were reanalysed by the proposed method and the percent recovery was reported. The results were given in Table No.4.

#### **Precision**

The repeatability of the method was verified by calculating the % RSD of three replicate injections of 100% concentration (30 $\mu$ g/ml of Teneligliptin) on the same day and for intraday precision % RSD was calculated from repeated studies. The results were given in Table No.5.

#### **Limit of Quantitation (LOQ) and Limit of Detection (LOD)**

The LOD and LOQ were calculated from the slope(s) of the calibration plot and the standard deviation (SD) of the peak areas using the formulae LOD = 3.3 s/s and LOQ = 10 s/s.

#### **Robustness**

Robustness was verified by altering the chromatographic conditions like mobile phase composition, flow rate, detection wave length, etc. and the % RSD should be reported. In the operational conditions Small changes were allowed and the extent to which the method was robust was determined. A deviation of  $\pm 2$ nm in the detection wave length and  $\pm 0.1$ ml/min in the flow rate, were tried individually. Solutions of 100% test concentration with the specified changes in the operational conditions were injected to the instrument in triplicate. % RSD was reported in the Table No.6.

#### **Assay of marketed formulation**

20 tablets of teneligliptin were weighed and crushed into fine powder. The average weight of the tablet was calculated and the amount equivalent to 10mg of pure teneligliptin was dissolved in 10ml of solvent. From this stock solution 30ppm dilution was prepared and injected. The % purity was calculated by comparing the result with result obtained from 30ppm standard drug and are reported in Table No.7.

### System suitability

It was ensure that from the system suitability parameters, the method can generate results of acceptable accuracy and precision. System suitability was carried out with three injections of solution of 30 $\mu$ l/ml of Teneiglipitin in to the chromatographic system. Number of theoretical plates (N) obtained and calculated tailing factor (T) was reported in Table No.8.

## RESULTS AND DISCUSSION

### Linearity

It was clarify from the analytical method linearity as the ability of the method to obtain test results that are directly proportional to the analyte concentration, within a specific range. The peak area obtained from the HPLC chromatograph was plotted against corresponding concentrations to obtain the calibration graph. The results of linearity study (Figure No.1) gave linear relationship over the concentration range of 10 - 50 $\mu$ g/ml for metformin. From the regression analysis, a linear equation was obtained  $y = 54647x - 74133$ , and the goodness-of-fit ( $r^2$ ) was found to be 0.9968, indicating a linear relationship between the concentration of analyte and area under the peak.

### Accuracy

The accuracy of the method determines the closeness of results obtained by that method to the true value. From the results of accuracy testing it was showed that the method is accurate within the acceptable limits. The % RSD is calculated for the Teneiglipitin and all the results are within limits. Acceptable accuracy was within the range and not more than 2.0% RSD, as demonstrated in Table No.3.

### Precision

Precision is "the closeness of results obtained from multiple sampling of the same homogeneous sample under the prescribed conditions," and it is expressed in the form of relative standard deviation. The repeatability, intra-day and inter-day precision results are shown in the Table No.5. The RSD were calculated for all the results are within limits. Precision was not more than 2.0% RSD, as demonstrated in Table No.5.

### LOD and LOQ

The LOD and LOQ were calculated by the equations  $LOD = \frac{3.3 \times \text{std. Deviation}}{\text{slope}}$  and  $LOQ = \frac{10 \times \text{std. Deviation}}{\text{slope}}$  where, std. Deviation taken from accuracy and slope is from linearity. Based on these equations, the calculated LOD and LOQ values for Teneiglipitin were 0.109 and 0.3305 $\mu$ g/ml, respectively.

### Robustness

Robustness of the method reflects that the results are unaffected or reliable even if the minute changes in the method parameters. Here, the flow rate and wavelength were slightly changed to lower and higher sides of the actual values to find if the change in the peak area and retention time were within limits. The results obtained with changes in the parameters on a 30 $\mu$ g/mL solution are as shown in Table No.6.

### Assay of marketed formulation

The % purity obtained from the formulation was given in Table No.7. And it was found that the Assay results of teneiglipitin are within the limits.

### System Suitability Parameters

System suitability was performed by injecting three replicate injections of 100% test concentration, number of theoretical plate, asymmetry factor are satisfactory. The chromatographs confirm the presence of Teneiglipitin at 4.2 min without any interference.

S.No	Parameter	Condition
1	Column	Cosmosil C18 (250mm x 4.6ID, Particle size: 5 micron)
2	Mobile Phase	70: 30 (Methanol: Phosphate buffer pH-3).
3	Flow Rate	0.8 ml/min
4	Wavelength	246 nm
5	Injection Volume	20 µl
6	Detector	UV-3000-M
7	Run Time	7.5 min
8	Retention Time	Approx. 4.2 min

S.No	Conc. (µg/ml)	Peak Area
1	10	465398
2	20	974059
3	30	1629073
4	40	2146136
5	50	2611705

S.No	Conc.	Area	Standard Deviation		Accuracy	Precision
			Mean	SD	%SD	%RSD
1	10	465631				
	10	465398	465321	354.8224908	0.0762533	0.076253273
	10	464934				
2	30	1632648				
	30	1629073	1629730	2651.272713	0.1626817	0.162681715
	30	1627469				
3	50	2608954				
	50	2611705	2611474.667	2413.756478	0.0924289	0.092428868
	50	2613765				



S.No	% Composition	Area of Standard	Area of Sample	% Recovery
1	50% Recovery	1629073	1633181	100.252168
2	100% Recovery	2146136	2112757	98.44469316
3	150% Recovery	2611705	2619697	100.306007

S.No		Inter day	Day 1			Day 2			Mean	%RSD
1	Injection	1	2	3	1	2	3			
2	area	1629073	1622953	1634124	1628514	1634567	1624254	1628914	0.30%	
3		Intraday	Morning			Evening			%RSD	
4	Injection	1	2	3	1	2	3			
5	area	1628102	1629073	1626134	1627963	1634124	1629163	1629093	0.17%	

S.No	Parameter	Condition	Peak Area	Statistical Analysis	Retention Time	Statistical Analysis		
1	Flow Rate ml/min	0.7	692412	Mean = 692318.444	4.339	Mean = 4.34666667		
			692352		4.383			
			692406		4.318			
		0.8	692265		4.203			
		0.9	692423	Mean = 692300.333	4.218	Mean = 4.242		
			692352		4.227			
692126	4.281							
2	Wavelength (nm)	236	687862	Mean = 689642.556	4.213	Mean = 4.20933333		
			688961		4.209			
			687423		4.206			
		238	692265		4.203			
		239	688413	Mean = 688580.667	4.206	Mean = 4.20566667		
			688367		4.203			
			688962		4.208			
						SD = 64.4380265		
						%RSD = 0.00930757		
				SD = 2284.74906				
				%RSD = 0.33129467				

S.No	% Composition	Area of Standard	Area of Sample	% Assay
1	% Assay	1629073	1622184	99.5771

S.No	Parameter	Observed Value	limits
1	No. of Theoretical Plates	9520	> 2000
2	Tailing Factor	1.15	<1.5



### CONCLUSION

The developed method was found to be accurate, simple, precise, rapid and specific for estimation of Teneligliptin from pure and its dosage forms. The mobile phase used for method development is very simple to prepare and economical also. The sample recoveries in the formulation were showing good

results with their respective label claims and it was found that there is no interference of formulation excipients in the estimation. And hence, this method can be easily and conveniently adopted for routine analysis of Teneligliptin in pure form and its dosage form.

## ACKNOWLEDGEMENT

Authors gratefully acknowledged to the Principal Dr. N S Vyawahare sir and Dr. Shilpa Chaudhari for their kind help and also thanks to Watson Pharma (A TEVA COMPANY) for providing all necessary facilities.

## CONFLICT OF INTEREST

We declare that we have no conflict of interest.

## BIBLIOGRAPHY

1. Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y, Tsukamoto T. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes, *Int Urol Nephrol*, 46(2), 2014, 427-432.
2. <https://www.drugbank.ca/drugs/DB11950>.
3. Awadhesh Kumar Singh. Efficacy and safety of teneligliptin, *Indian J Endocrinol Metab*, 21(1), 2017, 11-17.
4. Beckett A H, Stenlake J B. Instrumental methods in the development and use of medicines, In, Practical pharmaceutical chemistry (Part-2), CBS Publishers and Distributors, New Delhi, 4<sup>th</sup> Edition, 2005, 602.
5. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes, *Diabetes Metab Syndr Obes*, 6, 2013, 187-195.
6. Sean C Sweetman. Martindale: The complete drug reference, London (UK): Pharmaceutical Press (An Imprint of RPS Publishing), 1, 36<sup>th</sup> Edition, 2009.
7. Vishnu C. Shinde, Kiran B. Aher, Girija B. Bhavar, Sachin J. Kakad and Sanjay R. Chaudhari. Development and validation of UV spectrophotometric method and high performance thin layer chromatographic (HPTLC) method for estimation of Teneligliptin Hydrobromide in pharmaceutical preparation, *Der Pharmacia Lettre*, 8(8), 2016, 291-301.
8. Ganesh Kumar T N V, Vidyadhara S, Niteen Ashok Narkhede, Sai Silpa Y and Rajya Lakshmi M. Method development, validation and stability studies of Teneligliptin by RP-HPLC and identification of degradation products by UPLC tandem mass spectroscopy, *Journal of Analytical Science and Technology*, 7, 2016, 01-08.
9. Atul T. Hemke, Rathod E A, Gupta K R, Umekar M J. HPLC and UV-Spectrophotometric estimation of Teneligliptin from tablet dosage form, *Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry*, 4(3), 2016, 148-156.
10. Manjusha D. Karad and Barhate V D. Spectrophotometric determination of an anti diabetic drug Teneligliptin bulk and pharmaceutical formulations, *World Journal Pharmaceutical Research*, 5(5), 2016, 1625-1632.
11. Chunduri R H B, Dannana G S. Development and validation of LC-MS/MS method for quantification of teneligliptin in human plasma and its application to a pharmacokinetic study, *World Journal of Pharmacy and Pharmaceutical Sciences*, 5(5), 2016, 833-850.
12. Chen X W, He Z X, Zhou Z W, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus, *Clin Exp Pharmacol Physiol*, 42(10), 2015, 999-1024.

**Please cite this article in press as:** Shubham Bonde et al. A new RP-HPLC method development and validation of teneligliptin in bulk and tablet dosage form, *Asian Journal of Research in Chemistry and Pharmaceutical Sciences*, 7(3), 2019, 831-837.